Interplay between the Genetics of Personality Traits, severe Psychiatric Disorders, and COVID-19 Host Genetics in the Susceptibility to SARS-CoV-2 Infection

Urs Heilbronner¹, Fabian Streit², Thomas Vogl¹, Fanny Senner¹,³, Sabrina K. Schaupp¹, Daniela Reich-Erkelenz¹, Sergi Papiol¹,³, Mojtaba Oraki Kohshour¹,⁴, Farahnaz Klöhn-Saghatolislam¹,³, Janos L. Kalman¹,³, Maria Heilbronner¹, Katrin Gade⁵, Ashley L. Comes¹, Monika Budde¹, Till F. M. Andlauer⁶, Heike Anderson-Schmidt⁵, Kristina Adorjan¹,³, Til Stürmer⁷, Adrian Loerbroks⁸, Manfred Amelang⁹, Eric Poisel², Jerome Foo², Stefanie Heilmann-Heimbach¹⁰, Andreas J. Forstner¹⁰,¹¹, Franziska Degenhardt¹⁰,¹², Jörg Zimmermann¹³, Jens Wiltfang⁵, Martin von Hagen¹⁴, Carsten Spitzer¹⁵, Max Schmauss¹⁶, Eva Reininghaus¹⁷, Jens Reimer¹⁸, Carsten Konrad¹⁹, Georg Juckel²⁰, Fabian U. Lang²¹, Markus Jäger²¹, Christian Figge²², Andreas J. Fallgatter²³, Detlef E. Dietrich²⁴,²⁵, Udo Dannlowski²⁶, Bernhardt T. Baune²⁷,²⁸,²⁹, Volker Arolt²⁶, Ion-George Angelescu³⁰, Markus M. Nöthen¹⁰, Stephanie H. Witt², Ole A. Andreassen³¹,³², Chi-Hua Chen³³, Peter Falkai³, Marcella Rietschel², Thomas G. Schulze¹,³,⁴,³⁵,³⁶,³⁷,³, Eva C. Schulte¹,³,³⁷,³, *[NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.]*
ABSTRACT

Background
The SARS-CoV-2 pandemic, with all its impacts on our way of life, is affecting our experiences and mental health. Notably, individuals with mental disorders have been reported to have a higher risk of contracting SARS-CoV-2. Personality traits could represent an important determinant of preventative health behavior and, therefore, the risk of contracting the virus.

Aims
We examined overlapping genetic underpinnings between major psychiatric disorders, personality traits, and susceptibility to SARS-CoV-2 infection.

Methods
Linkage disequilibrium score regression was used to explore the genetic correlations of COVID-19 susceptibility with psychiatric disorders and personality traits based on data from the largest available respective genome-wide association studies (GWAS). In two cohorts (the PsyCourse (n=1346) and the HeiDE (n=3266) study), polygenic risk scores were used to analyze if a genetic association between, psychiatric disorders, personality traits, and COVID-19 susceptibility exists in individual-level data.

Results
We observed no significant genetic correlations of COVID-19 susceptibility with psychiatric disorders. For personality traits, there was a significant genetic correlation for COVID-19 susceptibility with extraversion (p=1.47x10−5; rg=0.284).
Yet, this was not reflected in individual-level data from the PsyCourse and HeiDE studies.

Conclusions
We identified no significant correlation between genetic risk factors for severe psychiatric disorders and genetic risk for COVID-19 susceptibility. Among the personality traits, extraversion showed evidence for a positive genetic association with COVID-19 susceptibility, in one but not in another setting. Overall, these findings highlight a complex contribution of genetic and non-genetic components in the interaction between COVID-19 susceptibility and personality traits or mental disorders.
INTRODUCTION

The global spread of SARS-CoV-2 has revealed differences in susceptibility to and severity of SARS-CoV-2 infection at both the individual and the community level. Studies from different regions of the world suggest a rise in the incidence of psychiatric disorders due to the threat of the virus and the socioeconomic repercussions of preventive measures that have been implemented (1-3). Interestingly, a recent study observed that a psychiatric diagnosis prior to SARS-CoV-2 infection was significantly associated with a higher risk of COVID-19 diagnosis (4); this risk was independent of known physical risk factors and living conditions. Personality traits (i.e. relative stable patterns of feelings, thoughts and behavior) might influence disease risk by mediating health-related behaviors such as the adherence to health regulations and recommendations (e.g., social distancing or mask wearing). In line with this, studies support an inverse relationship between extroversion and likelihood to engage in social distancing behavior at the beginning of the pandemic(5, 6).

The genetic underpinnings of psychiatric traits are known to not only show a large overlap among each other (7) but also with other diseases such as metabolic disorders(8, 9). An increased load of infections in individuals with psychiatric disorders has also been reported and may, in part, be due to shared genetic liability(10), although only few large-scale studies have tried to answer this question to date. In addition to very many other factors ranging from sex to pre-existing medical conditions and socioeconomic factors (11, 12), both common and rare genetic variants have been identified that may predispose individuals to an infection with SARS-CoV-2 or a severe course of COVID-19(13-15). A recent GWAS by the COVID-19 host genetics initiative (COVID-19 HGI(16)), identified 13 loci of genome-wide significance for the susceptibility to COVID-19, comparing subjects with self- or
physician-reported COVID-19 diagnosis to the general population. Four of these loci seem to be specific to COVID-19 susceptibility rather than disease severity. The identified loci include variants in genes implicated in the innate immune response to viruses but also genomic loci harboring many genes of yet-undetermined function in the context of COVID-19.

In light of these findings, we asked whether genetic underpinnings are shared between COVID-19 susceptibility, major psychiatric disorders, and personality traits. We approached this question using both results from the largest GWAS in the respective fields and individual-level data from two observational studies of psychiatric disorders (PsyCourse) and personality traits (PsyCourse and HeiDE).

METHODS
We performed linkage disequilibrium score regression (LDSC) (17) to calculate genetic correlations(18) between susceptibility to COVID-19 and psychiatric disorders as well as personality traits. We used summary statistics for COVID-19 susceptibility derived from a genome-wide association study (GWAS) performed by the COVID-19 Host Genetics Initiative(16) (self- or physician-reported COVID-19 diagnosis (n=87,870) vs. general population (n=2,210,804); analysis “C2” for European ancestry without 23andMe, Inc., release 6, downloaded from https://www.covid19hg.org/results/r6/, accessed July 30, 2021). For psychiatric disorders, summary data from the following GWAS were used: schizophrenia (SCZ; 33,640 cases; 43,456 controls)(19), bipolar disorder (BPD; 41,917 cases; 371,549 controls)(20), depression (as a broader phenotype closely related to major depressive disorder (MDD)) (246,363 cases; 561,190 controls)(21), and Big 5 personality traits (n=70,000 to 120,000)(22). For the details on phenotype definitions used in the GWAS, please refer to the original publications.
In a second step, individual-level data were used to calculate polygenic risk scores (PRS). In the PsyCourse Study (n=1786), consisting of individuals with major psychiatric disorders (652 SCZ, 567 BPD, 101 MDD) and controls without major psychiatric disorders (n=466), recruited throughout Germany and Austria and followed longitudinally(23), we assessed whether PRS for susceptibility to COVID-19 were associated with case status or with extraversion scores. PRS were calculated using the PRS-CS method(24), excluding the HLA region on chromosome 6. All genotyped participants of the PsyCourse Study with a diagnosis from the psychotic-to-affective spectrum as well as controls (n=1346, age [mean±SD] 47.75±13.81, 47.39% female) or for whom an extraversion score was available (n= 1190) were included in the analysis. “Case” status was defined as having a lifetime diagnosis of a severe psychiatric disorder from the spectrum of psychotic and affective disorders defined in the DSM-IV and as determined by a trained rater administering the relevant section of the SCID-I interview. The extraversion score (range: 1 to 5, mean: 3.09) was derived from a 10-item questionnaire assessing the Big 5 Personality Traits(25) (Figure). DNA samples of PsyCourse participants were genotyped on the Illumina Infinium PsychArray, and imputed using the 1000 Genomes project dataset as reference panel (for details, see(23)).

In the HeiDE study (e.g.(26)), we assessed whether extraversion scores (see below) were associated with PRS for COVID-19 susceptibility (generated using PRS-CS; n=3266, age [mean±SD] 52.78±7.06, 52.38% female). Briefly, HeiDE (“Heidelberger Langzeitstudie zu Risikofaktoren und Diagnose chronischer Erkrankungen”) is a population-based study carried out in the German city of Heidelberg and surroundings, whose initial aim was to characterize associations of personality and somatic disease. Data analyzed in this study were collected during the baseline assessment (personality traits; 1992 to 1994) and the first follow-up (DNA for
genotyping; on average 8.5 years after baseline). Extraversion was measured using the Eysenck-Personality-Inventory, from which we analyzed the sum of two items closely matching the items of the Big 5 personality questionnaire used in the PsyCourse study (range: 0 to 2, mean: 1.48). DNA samples of HeiDE participants were genotyped using the Illumina Infinium PsychArray and the Infinium OmniExpress Exome Array. The combined HeiDE datasets were imputed using the 1000 Genomes phase 3 reference panel (for details, see(27)). Also see the figure for an overview of the study design.

PRS scoring and association testing using linear or ordinal regressions were implemented in PLINK (version 1.9) and R (version 4.0.3). In both studies, we regressed the respective phenotype onto age, age², sex, and the first eight ancestry multi-dimensional scaling components (backward stepwise regression). The residuals of the final model were then regressed onto the PRS (PsyCourse), or the final model was compared to a model additionally containing the PRS (HeiDE). As far as we know, there is no overlap between individuals from the PsyCourse and HeiDE studies and the GWAS, whose summary statistics were used for the LDSC above.

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects were approved by the Institutional Review Board at the University of Munich (13-17), the Institutional Review Board at the Medical Faculty of the University of Heidelberg (026/2001), or the local review boards of the primary studies that the utilized summary statistics were taken from(16, 19-22, 28). Written informed consent was obtained from all study subjects.
RESULTS
No genetic correlation was found between COVID-19 susceptibility and MDD, BPD, or SCZ risk (Table 1). When analyzing the genetic correlation between personality traits(22) and COVID-19 susceptibility, a significant positive correlation ($p=1.47 \times 10^{-5}$; $rg=0.284$) was identified for the personality trait of extraversion. No statistically significant correlation was present with any other Big-5 personality trait (Table 2).

To corroborate these findings by a second, independent line of evidence using individual-level data from two independent cohorts, we turned to an assessment of PRS. In the PsyCourse Study, PRS for COVID-19 susceptibility were not significantly associated with psychiatric case status when compared to controls ($p=0.474$, $\beta=-1.132$). Further, in the PsyCourse Study, no significant association between COVID-19 susceptibility PRS and extraversion as measured by the 10-item questionnaire assessing the Big-5 Personality Traits ($p=0.210$, $\beta=2.369$) was found.

To validate the finding for extraversion in another study setting and to mitigate any potential influence of an interaction between psychiatric disorders and personality traits in the context of COVID-19 susceptibility possibly present in the PsyCourse study, we recapitulated the extraversion analysis in the larger HeiDE study which was specifically designed to evaluate the interaction between personality traits and somatic disorders. Here, however, we also did not detect a significant association of PRS for COVID-19 susceptibility and extraversion (model comparison $p=0.758$, AIC 5149.51 [model with PRS] and AIC 5147.60 [model without PRS]).

DISCUSSION
It is likely that many interdependencies exist between COVID-19 susceptibility and major psychiatric disorders or personality traits. Among these, we shed light on a potential role for shared common genetic risk factors. For major psychiatric
disorders, we did not identify a significant genetic overlap that can be ascribed to common genetic variation both when assessing summary statistics of large GWAS by LDSC and when looking at PRS in individual level data, in line with emerging data in the field\(^{(16, 29, 30)}\). With regard to personality traits, the picture is more heterogeneous with a significant signal for a positive genetic correlation between extraversion and COVID-19 susceptibility by LDSC, which needs to be explored further once larger data sets become available. However, it has to be assumed, that the genetic make-up is only one contributor in a very complex network of factors connecting extraversion to COVID-19 susceptibility.

The positive correlation identified between COVID-19 susceptibility and extraversion highlighted by the LDSC approach appears to be in line with the literature. Numerous studies performed both before and during the SARS-CoV-2 pandemic have demonstrated the effect of personality determinants on health behavior and outcomes \((e.g.\,(5, 31, 32))\). For example, it was shown that narcissistic tendencies coincide with decreased perceived susceptibility to infection with SARS-CoV-2\(^{(33)}\) while, at least for neuroticism, not genetic overlap was found\(^{(29)}\). Intuitively, less extroverted individuals may find social distancing during the pandemic easier than extroverted individuals and may, therefore, be more compliant with social distancing rules and at an overall decreased risk for COVID-19\(^{(5, 6)}\). There is even evidence of a bidirectionality of this phenomenon—the general risk for infectious diseases in a given region may, in part, influence personality traits at population level such that lower mean levels of extraversion are reported in regions with higher prevalence of infectious diseases\(^{(34)}\). One possible reason for this could be that in regions where ever-present infectious diseases present a comparatively large threat to health and well-being, less extraversion is present at population level either because people have adapted their behavior or because of potential selective pressure. Yet, it is
likely that many interdependencies exist between COVID-19 susceptibility and personality traits or major psychiatric disorders and we investigated only shared common genetic risk factors.

Although all included GWAS are the currently largest in the respective fields, sample sizes may still not be large enough to confidently detect genetic correlations in settings with many natural confounders such as levels of exposure to the virus or socioeconomic differences, to name only a few. Also, different instruments where used to evaluate personality traits in PsyCourse and HeiDE and the study populations (individuals with severe psychiatric disorders and controls vs. the general population) were different, possibly contributing to the observed heterogeneity. While LDSC represents a powerful tool to assess genetic correlations, other methods to quantify polygenic overlap irrespective of genetic correlations also exist (e.g.,(35)) and could be used to explore potential shared genetic underpinnings in even greater depth but are beyond the scope of this study. An additional limitation lies in the fact that no direct risk assessment was possible for the individuals with individual-level data on major psychiatric disorders and personality traits since no COVID-19 phenotypes were available. Lastly, we are unable to fully exclude sample overlap especially on the side of the controls used in the included GWAS. However, LDSC results should be robust to both of these overlaps(18).

Hypothetically, it is possible that—for example—only a small subset of common genetic risk factors in a given pathway relevant to major psychiatric disorders or personality traits is associated with COVID-19 susceptibility. Although we cannot fully exclude all such effects, our data suggest that non-genetic factors play important roles in the interplay between personality traits and COVID-19.

A direct genetic overlap is unlikely to contribute to the increased, but yet-unexplained COVID-19 risk seen in individuals with a psychiatric diagnosis prior to SARS-CoV-2.
infection (4) but a shared genetic risk could still be mediated by intermediate phenotypes such as, for example, lower socio-economic status or educational attainment in those with severe psychotic disorders. As a consequence, an even greater focus should be placed on psychosocial interventions, ensuring the best treatment for individuals with severe psychiatric disorders as well as targeted measures of prevention and psychoeducation for individuals with personality determinants that place them at an increased pandemic-related risk for health and well-being.

REFERENCES

Preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
All rights reserved. No reuse allowed without permission.

29. Chang XL, Yun; Nguyen, Kenny; Qu, Huiji; Liu, Yichuan; Glessner, Joseph; Sleiman, Patrick M. A.; Hakonarson, Hakon. Genetic correlations between COVID-19 and a variety of traits and diseases. 2021.

AFFILIATIONS

1Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Nussbaumstr 7, Munich, 80336, Germany

2Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, 68159, Germany

3Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Nussbaumstr 7, Munich, 80336, Germany

4Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

5Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, 37075, Germany

6Department of Neurology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, 81675, Germany

7Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

8Institute of Occupational, Social, and Environmental Medicine, Centre for Health and Society, Faculty of Medicine, University of Düsseldorf, Düsseldorf, Germany

9Department of Psychology, University of Heidelberg, Hauptstraße 47-51, Heidelberg

10Institute of Human Genetics, University of Bonn School of Medicine & University Hospital Bonn, Venusberg-Campus 1, Building 13, Bonn, 53127, Germany

11Institute of Neuroscience and Medicine (INM-1), Research Center Jülich, Jülich, 52428, Germany

12Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

13Psychiatrieverbund Oldenburger Land gGmbH, Karl-Jaspers-Klinik, Bad Zwischenahn, 26160, Germany

14Clinic for Psychiatry and Psychotherapy, Clinical Center Werra-Meißner, Eschwege, 37269, Germany
15Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Rostock, Rostock, 18147, Germany

16Department of Psychiatry, Psychotherapy and Psychosomatics, Augsburg University, Medical Faculty, Bezirkskrankenhaus Augsburg, Augsburg, 86156, Germany

17Department of Psychiatry and Psychotherapeutic Medicine, Research Unit for Bipolar Affective Disorder, Medical University of Graz, Graz, 8036, Austria

18Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, 20246, Germany

19Department of Psychiatry and Psychotherapy, Agaplesion Diakonieklinikum, Rotenburg, 27356, Germany

20Department of Psychiatry, Ruhr University Bochum, LWL University Hospital, Bochum, 44791, Germany

21Department of Psychiatry II, Ulm University, Bezirkskrankenhaus Günzburg, Günzburg, 89312, Germany

22Karl-Jaspers Clinic, European Medical School Oldenburg-Groningen, Oldenburg, 26160, Germany

23Department of Psychiatry and Psychotherapy, Tübingen Center for Mental Health, University Tübingen, Tübingen, 72076, Germany

24AMEOS Clinical Center Hildesheim, Hildesheim, 31135, Germany

25Center for Systems Neuroscience Hannover, Hannover, 30559, Germany

26Institute for Translational Psychiatry, University of Münster, Münster, 48149, Germany

27Department of Psychiatry, University of Münster, Münster, 48149, Germany

28Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Australia

29The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia

30Department of Psychiatry and Psychotherapy, Mental Health Institute Berlin, Berlin, 14050, Germany

31NORMENT Centre and KG Jebsen Centre for Neurodevelopmental disorders, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

32Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway

33Department of Radiology, University of California, San Diego, CA, USA

34Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, 50 East Adams Street, Syracuse, NY, 13210, USA

35Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, 1800 Orleans St, Baltimore, MD, 21287, USA

36Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, Mannheim, 68159, Germany

37Institute of Virology, Technical University Munich/Helmholtz Zentrum München, Trogerstr 30, Munich, 81675, Germany
shared senior authors

*Corresponding author:

Eva C. Schulte, MD, PhD
Institute of Psychiatric Phenomics and Genomics (IPPG)
University of Munich
Nussbaumstr 7
80336 Munich
Germany
Email: eva.schulte@med.uni-muenchen.de
Phone: +49 89 4400 55560
Mobile: +49 176 62178157

DECLARATION OF INTEREST

MS is a member of the advisory board of Janssen. BTB reports the following COIs:
Advisory Board—Lundbeck, Janssen-Cilag; Consultant—National Health and Medical Research Council, Australia; Grant/Research Support—AstraZeneca, Fay Fuller Foundation, James & Diana Ramsay Foundation, National Health and Medical Research Council, Australia, German Research Council (DFG), Sanofi, Lundbeck; Honoraria—AstraZeneca, Bristol-Myers Squibb, Lundbeck, Pfizer, Servier Laboratories, Wyeth Pharmaceuticals, Takeda, Janssen, LivaNova PLC. OAA has received speaker’s honorarium from Lundbeck and Synovion, and is a consultant to HealthLytix. All other authors do not report conflicts of interest with regard to this manuscript.

ACKNOWLEDGEMENTS & FUNDING

We are extremely grateful to all members of the COVID-19 Host Genetics Initiative for rapidly sharing data in an open-science fashion and to all study participants of all the studies included in the COVID-19 Host Genetics Initiative (https://www.covid19hg.org/acknowledgements/), the PsyCourse Study
(http://www.psycourse.de), and the HeiDE Study without whose contributions this work would not have been possible. Further, our work also depended upon the sharing of summary statistics from the large GWAS on SCZ, BPD, and MDD performed by the Psychiatric Genomics Consortium (PGC) and as well as the authors and participants of the Big 5 GWAS performed by Lo et al. We would like to thank the research participants and employees of 23andMe for making this work possible. MMN and ECS are members of the German COVID-19 Omics Initiative (DeCOI). MMN is member of the DFG-funded Excellence Cluster ImmunoSensation2 (EXC 2151 – 390873048). This study was supported by ERA-NET NEURON grants “EMBED” (01EW1904 to MR), and “SynSchiz—Linking synaptic dysfunction to disease mechanisms in schizophrenia—a multilevel investigation” (01EW1810 to MR). TGS and PF are supported by the German Research Foundation (Deutsche Forschungsgemeinschaft; DFG) within the framework of the projects www.kfo241.de and www.PsyCourse.de (SCHU 1603/4-1, 5-1, 7-1; FA241/16-1), ECS is also supported by the DFG (SCHU 2419/2-1) and through the Munich Clinician Scientist Program (MCSP). The genotyping was in part funded by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent (Integrated Understanding of Causes and Mechanisms in Mental Disorders), under the auspices of the e:Med Program with grants awarded to TGS (01ZX1614K), MR (01ZX1614G), and MMN (01ZX1614A). TGS received additional support from the German Federal Ministry of Education and Research (BMBF) within the framework of the BipoLife network and the Dr. Lisa Oehler Foundation, Kassel (Germany). OAA received support from Research Council of Norway (#223273, #283798, #248980) and NordForsk (#105668).

We thank Stefan Herms for his support in the technical provision of genotype data.
AUTHOR CONTRIBUTIONS

Formulation of research question: UH, FS, MR, TGS, ECS

Study design: UH, FS, TS, AL, MA, OAA, CHC, PF, MR, TGS, ECS

Study conduction: UH, TV, FS, SKS, DRE, FKS, JLK, MH, KG, ALC, MB, HAS, KA, TS, AL, MA, JZ, JW, MVH, CS, MS, ER, JR, CK, GJ, FUL, MJ, CF, AJFa, DED, UD, BTB, VA, IGA, MMN, SHH, AJFo, FD, SHW, OAA, CHC, PF, MR, TGS, ECS

Data analysis: UH, FS, SP, MOK, TFMA, EP, JF, OAA, CHC, ECS

Manuscript writing: UH, FS, ECS

Critical revision of manuscript: all authors

DATA AVAILABILITY

The data that support the findings in this study are available from the corresponding author, ECS, upon reasonable request. The relevant summary statistics from the GWAS used in the analyses are available from the authors of the primary studies (16, 19-22, 28). Interested researchers can also apply for the used as well as additional data for the PsyCourse Study via http://www.psycourse.de/openscience-en.html.
Figure: Study design for PRS analyses. Summary statistics from the to-date largest genome-wide association study on susceptibility to COVID-19 performed by the COVID-19 Host Genetics Initiative were used to generate polygenic risk scores. These were then tested for association with case/control status for severe psychiatric disorders such as schizophrenia, bipolar disorder, or major depressive disorder (PsyCourse Study only) as well as measures of extraversion (PsyCourse and HeiDE studies).

TABLES

<table>
<thead>
<tr>
<th>Trait</th>
<th>MDD(21)</th>
<th>BPD(20)</th>
<th>SCZ(19)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rg</td>
<td>0.072</td>
<td>0.004</td>
<td>-0.037</td>
</tr>
<tr>
<td>SE</td>
<td>0.044</td>
<td>0.045</td>
<td>0.044</td>
</tr>
<tr>
<td>p-value</td>
<td>0.100</td>
<td>0.930</td>
<td>0.398</td>
</tr>
</tbody>
</table>

Table 1: Results from LDSC between COVID-19 susceptibility and severe psychiatric disorders. MDD= major depressive disorder, BPD= bipolar disorder, SCZ= schizophrenia, rg= genetic correlation, SE= standard error.
<table>
<thead>
<tr>
<th>Trait</th>
<th>Agreeableness</th>
<th>Conscientiousness</th>
<th>Extraversion</th>
<th>Neuroticism</th>
<th>Openness</th>
</tr>
</thead>
<tbody>
<tr>
<td>rg</td>
<td>0.177</td>
<td>0.056</td>
<td>0.284</td>
<td>-0.105</td>
<td>-0.095</td>
</tr>
<tr>
<td>SE</td>
<td>0.093</td>
<td>0.079</td>
<td>0.066</td>
<td>0.071</td>
<td>0.067</td>
</tr>
<tr>
<td>p-value</td>
<td>0.057</td>
<td>0.478</td>
<td>1.47E-5</td>
<td>0.142</td>
<td>0.153</td>
</tr>
</tbody>
</table>

Table 2: Results from LDSC between COVID-19 susceptibility and Big 5 Personality Traits. The p-value for genetic correlation between extraversion and COVID-19 susceptibility was statistically significant. rg=genetic correlation, SE=standard error.